Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Carcinoid Tumor Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market size of carcinoid tumors has experienced substantial growth in the past few years. The figures are set to escalate from $1.61 billion in 2024 to $1.77 billion in 2025, marking a compound annual growth rate (CAGR) of 10.4%. Factors contributing to growth during the historic period include an increased number of neuroendocrine tumor cases, heightened awareness of atypical cancers, advancements in healthcare infrastructure, the provision of focused therapies, and the augmentation of clinical trials for novel treatment alternatives.
The market size of carcinoid tumors is anticipated to witness a swift escalation in forthcoming years. The market is predicted to reach$2.62 billion by 2029″ with a compound annual growth rate (CAGR) of 10.3%. Factors contributing to this surge during the projection period are the burgeoning requirement for personalized medicine, escalating emphasis on early detection and diagnosis, increased preference for minimally invasive surgeries, flourishing research on innovative treatments, and a rise in the utilization of focused molecular therapies. Trends expected in the forecast period comprise the incorporation of artificial intelligence and machine learning in the diagnostic process, a move towards combined therapies, telemedicine and remote patient monitoring, patient-driven care, and cooperative research.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Carcinoid Tumor Market?
The increase in the obese population is predicted to fuel the expansion of the carcinoid tumor market in the future. The term “obese population” refers to people with a body mass index (BMI) of 30 or more, signaling an excess of body fat. The multiplication of this population can be traced back to factors like insufficient dietary practices, physical inactivity, stationary lifestyles, and the upsurge intake of processed and high-calorie edibles. The role of obesity in carcinoid tumor evolution is evident as it fosters chronic inflammation, impedes insulin functionality, and elevates the secretion of growth elements facilitating tumor enlargement. As an example, the Centers for Disease Control and Prevention, a government agency based in the USA, stated in September 2023 that the adult obesity rate in 22 states rose to 35% or more in 2022, an increase from 19 states the previous year. Hence, the expansion of the obese population is facilitating the growth of the carcinoid tumor market.
Which Primary Segments of the Carcinoid Tumor Market Are Driving Growth and Industry Transformations?
The carcinoid tumormarket covered in this report is segmented –
1) By Disease Type: Gastrointestinal Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Lung Neuroendocrine Tumor; Other Disease Types
2) By Treatment: Octreotide; Lanreotide; Telotristat ethyl; Capecitabine (Xeloda); 5-Fluorouracil (5-FU); Doxorubicin (Adriamycin); Etoposide (VP-16); Dacarbazine (DTIC); Streptozocin; Other Treatments
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Online Channel; Offline Channel
5) By End User: Hospital And Clinics; Academic Institutions; Research Organizations
Subsegments:
1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors; Appendiceal Neuroendocrine Tumors
2) By Pancreatic Neuroendocrine Tumor: Insulinoma; Non-insulinoma; Glucagonoma
3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors; Atypical Carcinoid Tumors
4) By Other Disease Types: Thymic Neuroendocrine Tumors; Ovarian Neuroendocrine Tumors
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21127&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Carcinoid Tumor Market?# Market?
North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Carcinoid Tumor Market?
Leading enterprises within the carcinoid tumor market are prioritizing advancements in diagnostic tools, such as the entirely automated chromogranin A examination, for better early detection and improved treatment results. The automated chromogranin A (CgA) test is a completely automated diagnostic instrument that quantifies chromogranin A levels, a biomarker frequently related to neuroendocrine and carcinoid tumors. For example, Thermo Fisher Scientific Inc., an American biotech research firm, obtained FDA approval in October 2023 for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This event marked the first FDA-sanctioned CgA test and the only automated immunoassay worldwide for tracking tumor development in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET). The specially designed assay measures CgA concentration in human plasma, allowing labs and cancer centers to monitor tumor growth and evaluate treatment effectiveness. The replacement of hand-operated laboratory-developed tests promotes laboratory productivity and provides clearer result analysis. The test is performed on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, deploying TRACE technology to furnish accurate results in less than 30 minutes.
View the full report here:
https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report
What Parameters Are Used to Define the Carcinoid Tumor Market?
A carcinoid tumor is a rare, slow-growing type of neuroendocrine tumor that typically arises in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms may vary depending on the tumor’s location and whether it secretes hormones, potentially causing carcinoid syndrome.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21127
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model